Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

  • Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

    Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

  • UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

    Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

  • SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

    Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M1TmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S4SWlEPTB;MD6wNFA{ODNizszN MoPqV2FPT0WU
IST-MEL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED0e|ZKSzVyPUCuNFAxPDB5IN88US=> M4nj[nNCVkeHUh?=
NCI-SNU-1 NIHCSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLOdHBnUUN3ME2wMlAxOjB5IN88US=> MmTYV2FPT0WU
FADU MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\FZXZ3UUN3ME2wMlAxOjB7IN88US=> NVO3c5ZZW0GQR1XS
C32 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETrN2JKSzVyPUCuNFA{ODRizszN M{nreHNCVkeHUh?=
D-566MG NYnwVGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvuTWM2OD1yLkCwN|kh|ryP MmDIV2FPT0WU
LXF-289 NYq3fW53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHM[2pKSzVyPUCuNFA1OTlizszN NIrVepJUSU6JRWK=
HGC-27 NX24b3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojSTWM2OD1yLkCwOVEh|ryP M1T5[nNCVkeHUh?=
RPMI-7951 NE\qcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;qTWM2OD1yLkCwO|E4KM7:TR?= M4LHcXNCVkeHUh?=
HSC-3 M1nzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT2TWM2OD1yLkCwPVI6KM7:TR?= NWO5dVNyW0GQR1XS
MIA-PaCa-2 MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEGwNFkh|ryP Mkf3V2FPT0WU
KS-1 M3LXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfpfnhXUUN3ME2wMlAyOzV3IN88US=> NGe5epZUSU6JRWK=
CAL-51 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\PT3NwUUN3ME2wMlAyPDB3IN88US=> NEfhWplUSU6JRWK=
MDA-MB-361 NYKyeY56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37iZmlEPTB;MD6wNVQ6PSEQvF2= NF6wSYdUSU6JRWK=
TI-73 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7YTWM2OD1yLkCxO|k3KM7:TR?= M2HVTHNCVkeHUh?=
AGS NWG5[HZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5OIp2UUN3ME2wMlAyQTN6IN88US=> NUno[ox1W0GQR1XS
NCI-H460 NH:zd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PNWWlEPTB;MD6wNVk4PCEQvF2= MXLTRW5ITVJ?
A204 NIDI[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEKyOFkh|ryP NVu5WGVHW0GQR1XS
CHL-1 M1TIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXoUppKSzVyPUCuNFIzPTFizszN MXrTRW5ITVJ?
DU-4475 M2W1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW4TWM2OD1yLkCyNlYyKM7:TR?= NFPFVVRUSU6JRWK=
CGTH-W-1 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjpTWM2OD1yLkCyN|Q6KM7:TR?= MkfmV2FPT0WU
HCC2218 M4j5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13JWmlEPTB;MD6wNlQ6PCEQvF2= NY\KUVF7W0GQR1XS
A2780 NEnYV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\COpZKSzVyPUCuNFI2OzFizszN MVzTRW5ITVJ?
NCI-H720 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XtdmlEPTB;MD6wNlU1PiEQvF2= NIXSU2VUSU6JRWK=
NCI-N87 NFflcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\YNmlEPTB;MD6wNlU6OyEQvF2= MY\TRW5ITVJ?
CHP-212 NUjkV25pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\4Z2lEPTB;MD6wNlYzQCEQvF2= NUjuTFNsW0GQR1XS
NCI-H23 MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrnTWM2OD1yLkCyOlY2KM7:TR?= NHzwSpJUSU6JRWK=
D-263MG NVHYdXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLD[4xKSzVyPUCuNFI4QDZizszN MX7TRW5ITVJ?
ME-180 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr1TWM2OD1yLkCyPFkyKM7:TR?= NVLKXYxsW0GQR1XS
SW982 NUTnSXF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[4XVlVUUN3ME2wMlAzQTl7IN88US=> NEnXVpRUSU6JRWK=
OE19 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMEOwO|ch|ryP NU\jOYd3W0GQR1XS
SK-LU-1 NVjSbYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL0PVFKSzVyPUCuNFMxQDJizszN M{HmWHNCVkeHUh?=
H4 M{D3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTkcpRKSzVyPUCuNFMxQSEQvF2= NXrUc|Y6W0GQR1XS
HT-144 M3ewOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvVemtRUUN3ME2wMlA{ODl|IN88US=> NWX1T3ZEW0GQR1XS
SK-UT-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLzPZpKSzVyPUCuNFMyPzhizszN NIK5fpZUSU6JRWK=
D-336MG NYfoUFNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfyXYpKSzVyPUCuNFM{ODlizszN MkXlV2FPT0WU
MDA-MB-175-VII NFHKXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M164[WlEPTB;MD6wN|M2PCEQvF2= NHvzZ2lUSU6JRWK=
GAMG NFLGemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEO0N|Uh|ryP M{\PVnNCVkeHUh?=
CP50-MEL-B MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:wTWM2OD1yLkCzOFUh|ryP Ml;tV2FPT0WU
OVCAR-5 NEHSSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjkcnVKSzVyPUCuNFM1QCEQvF2= NXO3RpBTW0GQR1XS
SK-MES-1 NGfzb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jJ[mlEPTB;MD6wN|YxPiEQvF2= MWLTRW5ITVJ?
VM-CUB-1 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorsTWM2OD1yLkCzOlU4KM7:TR?= MVnTRW5ITVJ?
WM-115 NEn4e5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL2ZWRKSzVyPUCuNFM4PjJizszN MmOxV2FPT0WU
DSH1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEO4NFch|ryP MknZV2FPT0WU
Becker NX7IToFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMEO4PFUh|ryP MXLTRW5ITVJ?
SW962 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:wb2lEPTB;MD6wN|k1PSEQvF2= NX;ZZ|FiW0GQR1XS
TYK-nu Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojnTWM2OD1yLkCzPVg2KM7:TR?= NVjJVXFqW0GQR1XS
HO-1-N-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLDTWM2OD1yLkC0NFIyKM7:TR?= MX;TRW5ITVJ?
T98G NX7Id5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi4[pI6UUN3ME2wMlA1OTB|IN88US=> MWjTRW5ITVJ?
ACN M2q4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMESxOlIh|ryP NXHl[YdiW0GQR1XS
SW780 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TTcmlEPTB;MD6wOFIxOyEQvF2= MWTTRW5ITVJ?
Detroit562 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HQO2lEPTB;MD6wOFI{QSEQvF2= Mmr4V2FPT0WU
BB49-HNC NYfSdYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PNSmlEPTB;MD6wOFI1OyEQvF2= NF\tdm5USU6JRWK=
HN NXzTSVhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWftXoR7UUN3ME2wMlA1Ojd{IN88US=> MUPTRW5ITVJ?
H9 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n4OmlEPTB;MD6wOFM4OSEQvF2= NIPoSlVUSU6JRWK=
VA-ES-BJ NEXuUldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMES0OFch|ryP NWDpPZl[W0GQR1XS
MEL-JUSO NUnCdINjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TOb2lEPTB;MD6wOFQ4PSEQvF2= MVfTRW5ITVJ?
BT-474 NGX4PHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjRe|hKSzVyPUCuNFQ2KM7:TR?= Ml;jV2FPT0WU
CaR-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\hRWMxUUN3ME2wMlA1PTR7IN88US=> NUnOeVYxW0GQR1XS
PSN1 NHnWR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO1[GM5UUN3ME2wMlA1PjB|IN88US=> M{PTOnNCVkeHUh?=
KYSE-510 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwTWM2OD1yLkC0OlQ6KM7:TR?= MVTTRW5ITVJ?
KP-4 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMES3OVMh|ryP Mo\DV2FPT0WU
KYSE-410 M121U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S2VmlEPTB;MD6wOFc4OiEQvF2= NFLBeoFUSU6JRWK=
G-402 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vCcmlEPTB;MD6wOFc5QSEQvF2= NIfmeJVUSU6JRWK=
DOK MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\mcWlEPTB;MD6wOFkxOiEQvF2= MXPTRW5ITVJ?
COR-L88 MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M374RmlEPTB;MD6wOFkyOiEQvF2= NXjRW4p3W0GQR1XS
SKG-IIIa Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofaTWM2OD1yLkC0PVg3KM7:TR?= M2PCfXNCVkeHUh?=
AN3-CA M1;QTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEWg{txO NV3JSIx2W0GQR1XS
SW48 NG\FfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\XRmNKSzVyPUCuNFUxOzlizszN NV71bmpJW0GQR1XS
YKG-1 NEmwcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm4clZzUUN3ME2wMlA2ODdzIN88US=> MXTTRW5ITVJ?
KYSE-150 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLNTWM2OD1yLkC1NlM2KM7:TR?= NYX6c4dNW0GQR1XS
HuO-3N1 NX;VPYtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEWyN|ch|ryP M3vuVXNCVkeHUh?=
LB1047-RCC NFXzSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnPXW1SUUN3ME2wMlA2Ojl4IN88US=> MVzTRW5ITVJ?
NCI-H2030 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEW0NVQh|ryP NVfMUIpnW0GQR1XS
YH-13 NVfVdHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fPOGlEPTB;MD6wOVczOiEQvF2= NVzQTGZbW0GQR1XS
5637 M1;HXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGzPYpKSzVyPUCuNFU4PCEQvF2= MVHTRW5ITVJ?
LOXIMVI NFH6RmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXZUFRFUUN3ME2wMlA2QDd{IN88US=> M2fWcHNCVkeHUh?=
GT3TKB NGD5[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfFdGJ1UUN3ME2wMlA2QTR{IN88US=> NFq1d2JUSU6JRWK=
TCCSUP MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPhTHhsUUN3ME2wMlA2QTZ2IN88US=> NGT6VoZUSU6JRWK=
EPLC-272H M3XieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOzW5QxUUN3ME2wMlA3OjB3IN88US=> M4O3OXNCVkeHUh?=
LU-99A NEDMcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnFWlBpUUN3ME2wMlA3OjN5IN88US=> NHL0XZNUSU6JRWK=
NCI-H1755 NILodIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwME[zOFEh|ryP NFjXTW5USU6JRWK=
KM12 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDZVHhwUUN3ME2wMlA3OzR6IN88US=> M3LMe3NCVkeHUh?=
SF295 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3YNFRoUUN3ME2wMlA3PDV{IN88US=> MXjTRW5ITVJ?
MZ2-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\IWFJbUUN3ME2wMlA3PTV|IN88US=> M{\3dXNCVkeHUh?=
HEC-1 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uyemlEPTB;MD6wOlU5QCEQvF2= MXzTRW5ITVJ?
SW684 M3jMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofDTWM2OD1yLkC2OVkyKM7:TR?= NHTzU5dUSU6JRWK=
SF539 NVT0e5B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LOZ2lEPTB;MD6wOlY5OSEQvF2= NEjWNmhUSU6JRWK=
GMS-10 NVO0[ohGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rpVmlEPTB;MD6wOlY6QSEQvF2= NHnNPGFUSU6JRWK=
MV-4-11 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO0cW1CUUN3ME2wMlA3QDB|IN88US=> MXrTRW5ITVJ?
HT-29 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu2TY1bUUN3ME2wMlA3QTF7IN88US=> MXTTRW5ITVJ?
23132-87 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3NGlNUUN3ME2wMlA3QTVizszN M4\XeXNCVkeHUh?=
SW620 NGPIe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEewNlYh|ryP M2XmXXNCVkeHUh?=
HCC1806 NYXlOW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEexN|Eh|ryP MlLKV2FPT0WU
Hs-578-T NWraPYg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEeyNFgh|ryP M13JRnNCVkeHUh?=
A2058 NEXydoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7NWWpKSzVyPUCuNFczOjhizszN M3OxSnNCVkeHUh?=
MEL-HO MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OzVmlEPTB;MD6wO|I2PSEQvF2= M1jNZnNCVkeHUh?=
HCC2998 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXrT5RKSzVyPUCuNFc{PDdizszN M3m1V3NCVkeHUh?=
HuO9 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r2bmlEPTB;MD6wO|U5QSEQvF2= MUTTRW5ITVJ?
CAL-39 NUPuNWwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLjdGJXUUN3ME2wMlA4PzZ4IN88US=> MVLTRW5ITVJ?
M14 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7JTWM2OD1yLkC3PVE{KM7:TR?= MWjTRW5ITVJ?
BFTC-909 NFjHUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHiN2FCUUN3ME2wMlA4QTZ7IN88US=> M3PabHNCVkeHUh?=
TE-11 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nYUmlEPTB;MD6wO|k6PiEQvF2= NHv3PYtUSU6JRWK=
TGBC1TKB NGf1PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEiwOFMh|ryP NHjaNXBUSU6JRWK=
L-363 M{OzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4dVVUUUN3ME2wMlA5OjB4IN88US=> M3W1cnNCVkeHUh?=
A431 M{fFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGyTWM2OD1yLkC4NlEh|ryP NUPYT3JvW0GQR1XS
MKN45 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C4W2lEPTB;MD6wPFIyQSEQvF2= M{\WWXNCVkeHUh?=
HT-1080 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\v[IlKSzVyPUCuNFg1OzlizszN MXXTRW5ITVJ?
OVCAR-8 NHjKOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PBXWlEPTB;MD6wPFYzOiEQvF2= MnzMV2FPT0WU
LCLC-97TM1 NF:0e49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLoTWM2OD1yLkC4O|I5KM7:TR?= NVLUOlluW0GQR1XS
M059J NW\Wb5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEmwNlch|ryP MUfTRW5ITVJ?
SK-MEL-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEmwOkDPxE1? MV\TRW5ITVJ?
TE-1 NILVeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEmyNFQh|ryP NYPDNmRYW0GQR1XS
KYSE-180 M{\oTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke3TWM2OD1yLkC5NlYzKM7:TR?= NUK1dmNnW0GQR1XS
D-247MG M1O5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnNXoJKSzVyPUCuNFk1PTVizszN NEDNPZdUSU6JRWK=
8-MG-BA M17sU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[0TWM2OD1yLkC5OFczKM7:TR?= MkDlV2FPT0WU
NCI-H1792 NYrkS5N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHqRlNKSzVyPUCuNFk3OThizszN NEnlWW9USU6JRWK=
MCF7 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;kXXdKSzVyPUCuNFk3PzdizszN M1nrRnNCVkeHUh?=
NCI-H2122 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEm3OFUh|ryP NYTNVWJLW0GQR1XS
EFO-27 NFzHdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDpTWM2OD1yLkC5PVk4KM7:TR?= MXfTRW5ITVJ?
LB2241-RCC NVy5XHRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUCwOVQh|ryP MlLZV2FPT0WU
SN12C MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP3fml{UUN3ME2wMlExOTB5IN88US=> NIfwdJVUSU6JRWK=
A498 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUCxPEDPxE1? NW\NRWRLW0GQR1XS
PANC-03-27 NHzRNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XZNGlEPTB;MD6xNFI5PiEQvF2= NInGS2JUSU6JRWK=
NCI-H1581 NFXZSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfVVFZRUUN3ME2wMlExOjlizszN MXnTRW5ITVJ?
U-87-MG MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLSNYNKSzVyPUCuNVA{ODdizszN MnjVV2FPT0WU
G-401 MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjQfoRqUUN3ME2wMlExOzV|IN88US=> M3LuSnNCVkeHUh?=
SiHa NHPaeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzLTJlKSzVyPUCuNVA1QDZizszN NVTZPZdSW0GQR1XS
U251 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7tOIJKSzVyPUCuNVA2OjVizszN NXXQXYk4W0GQR1XS
MMAC-SF M2Huc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PwemlEPTB;MD6xNFU{OSEQvF2= NYHmSoh4W0GQR1XS
BB65-RCC NYDHWJZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6zRW5KSzVyPUCuNVA2PTRizszN M4rtdnNCVkeHUh?=
NKM-1 NVjJ[VFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;udGlEPTB;MD6xNFY3PiEQvF2= NX30V4FOW0GQR1XS
HD-MY-Z NF;Uc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnEfYFmUUN3ME2wMlExQDd|IN88US=> M{jrS3NCVkeHUh?=
TGBC11TKB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXLZ2xPUUN3ME2wMlExQTB|IN88US=> M3vFZnNCVkeHUh?=
COLO-679 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHyNVJKSzVyPUCuNVEzOTFizszN MXrTRW5ITVJ?
TE-8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ISmlEPTB;MD6xNVI3PCEQvF2= M160[HNCVkeHUh?=
SK-MEL-28 NF71cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT6VHRVUUN3ME2wMlEyOzJzIN88US=> NUf2NFNKW0GQR1XS
SH-4 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjUTWM2OD1yLkGxN|U3KM7:TR?= NIDIUWlUSU6JRWK=
KALS-1 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWWGlEPTB;MD6xNVM6OyEQvF2= NF;YcGdUSU6JRWK=
RKO NXSyOYk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXznSmJRUUN3ME2wMlEyPzZ2IN88US=> MWLTRW5ITVJ?
OMC-1 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMUG3PVch|ryP MXzTRW5ITVJ?
BT-549 NV;OSVlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\McFhHUUN3ME2wMlEyPzl7IN88US=> M3rlOHNCVkeHUh?=
NCI-H28 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMUG4NVch|ryP Mn24V2FPT0WU
RXF393 NECzZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMUG5PFIh|ryP MnvPV2FPT0WU
COLO-829 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T3dmlEPTB;MD6xNlAxPSEQvF2= M{DBfHNCVkeHUh?=
HMV-II NYfuTXBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT3TWM2OD1yLkGyNFIh|ryP MYTTRW5ITVJ?
SW1990 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMUKxOVch|ryP NVTF[2hvW0GQR1XS
NCI-H1437 NFznfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHXcJR[UUN3ME2wMlEzOTV5IN88US=> MX3TRW5ITVJ?
SNB75 M3y0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjHTWM2OD1yLkGyNVY6KM7:TR?= NHrtXWFUSU6JRWK=
EW-3 M1v3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\hTnBKSzVyPUCuNVI3PjFizszN NUDES3JpW0GQR1XS
SAS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUK2PUDPxE1? M2nu[XNCVkeHUh?=
NCI-H1666 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwMUK3O|Qh|ryP MlPOV2FPT0WU
A375 Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M123cmlEPTB;MD6xNlc4QCEQvF2= M3zZUXNCVkeHUh?=
CAMA-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrqeYxtUUN3ME2wMlEzQTJ2IN88US=> NV3FdWZEW0GQR1XS
HuP-T4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG3dG9KSzVyPUCuNVI6PDNizszN M3;V[nNCVkeHUh?=
NCI-H292 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zPemlEPTB;MD6xN|EyKM7:TR?= M3LLUHNCVkeHUh?=
PC-14 M2O3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDCTWM2OD1yLkGzNlEyKM7:TR?= NE\LSpZUSU6JRWK=
BPH-1 NV\xN25[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1riXGlEPTB;MD6xN|QyKM7:TR?= MXfTRW5ITVJ?
GAK M3zHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzvTWM2OD1yLkGzOVY4KM7:TR?= MVXTRW5ITVJ?
VMRC-RCZ MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSxZlJKSzVyPUCuNVM4PjJizszN MnXyV2FPT0WU
SK-MEL-24 M1fRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMUO4O{DPxE1? NE\OTW9USU6JRWK=
LB831-BLC NF3p[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUO4PFMh|ryP NXjvNIhXW0GQR1XS
NCI-H2452 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUO5OVYh|ryP MlflV2FPT0WU
RT-112 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPoNZZRUUN3ME2wMlE1ODN3IN88US=> MWjTRW5ITVJ?
GP5d MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDKTWM2OD1yLkG0NVA1KM7:TR?= M2H1dHNCVkeHUh?=
LC-2-ad M3zvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmzbWxWUUN3ME2wMlE1OTJzIN88US=> NUnPU4F{W0GQR1XS
MPP-89 NHTBXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUSxNlUh|ryP MYDTRW5ITVJ?
NUGC-3 M{fWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\rPJVQUUN3ME2wMlE1PDd6IN88US=> NF;DZmVUSU6JRWK=
GI-1 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S5e2lEPTB;MD6xOFU2QCEQvF2= M2D6d3NCVkeHUh?=
HCC1419 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ryVGlEPTB;MD6xOFU4PiEQvF2= NXPI[Y1UW0GQR1XS
SW1573 NWHwd5JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoixTWM2OD1yLkG0O|U5KM7:TR?= MVzTRW5ITVJ?
NCI-H2347 M335V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMUS4N|kh|ryP MUXTRW5ITVJ?
Mewo M{H6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoftTWM2OD1yLkG0PFg6KM7:TR?= NHHJbmhUSU6JRWK=
639-V M2LONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LvTmlEPTB;MD6xOVAyOyEQvF2= NUP1bIY2W0GQR1XS
AsPC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n5fWlEPTB;MD6xOVIzPSEQvF2= M1;NPXNCVkeHUh?=
NCI-H1648 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjaS4Z3UUN3ME2wMlE2OjN{IN88US=> M4noVXNCVkeHUh?=
786-0 NHS1eHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S4S2lEPTB;MD6xOVM5OSEQvF2= MoHCV2FPT0WU
ETK-1 M3THPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HT[WlEPTB;MD6xOVkh|ryP MXPTRW5ITVJ?
BxPC-3 NYTsbmNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfzSY9KSzVyPUCuNVU6PjZizszN MlnCV2FPT0WU
CAL-62 M1LaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLNTWM2OD1yLkG2NVY6KM7:TR?= M1vLT3NCVkeHUh?=
HCC1937 NFrDRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G0[2lEPTB;MD6xOlI4PSEQvF2= MlqxV2FPT0WU
NCI-H1299 M1fwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMU[yPFUh|ryP NWm3RopsW0GQR1XS
SW1088 NFrMfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrXTWM2OD1yLkG2OFE{KM7:TR?= MoHMV2FPT0WU
FTC-133 NVjn[o04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfuTWM2OD1yLkG2OVQh|ryP MmnxV2FPT0WU
OC-314 M3vzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvsUVBNUUN3ME2wMlE3PjlizszN M3vlWnNCVkeHUh?=
SCC-9 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLlTWM2OD1yLkG2O|E3KM7:TR?= M3jBeXNCVkeHUh?=
HT-1376 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHWTWM2OD1yLkG2PVM3KM7:TR?= MY\TRW5ITVJ?
U-2-OS NU\mZ3BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG5TWM2OD1yLkG3NVc{KM7:TR?= M{\2SXNCVkeHUh?=
COLO-824 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLrbG9JUUN3ME2wMlE4Ojl2IN88US=> NV[4XJhFW0GQR1XS
BB30-HNC NIjVfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHJUXdKSzVyPUCuNVc{OyEQvF2= MmTmV2FPT0WU
NCI-H2087 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7neXRKSzVyPUCuNVc{PjhizszN NWT3dJFRW0GQR1XS
NCI-H2170 M4DXTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;STWM2OD1yLkG3OVM3KM7:TR?= NFvEXHNUSU6JRWK=
SK-OV-3 M4PxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HjNGlEPTB;MD6xO|U4OSEQvF2= MlvEV2FPT0WU
MZ7-mel NWHCdYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDYfXpbUUN3ME2wMlE4PjR7IN88US=> M4rDbHNCVkeHUh?=
NCI-H650 NWLWRZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f4VGlEPTB;MD6xO|Y5OiEQvF2= M3;aPHNCVkeHUh?=
KOSC-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXENoFKSzVyPUCuNVc4OzRizszN NF7kVJZUSU6JRWK=
SCC-4 NH3qZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jyW2lEPTB;MD6xO|c4PyEQvF2= MYXTRW5ITVJ?
MDA-MB-157 M4XURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K3SWlEPTB;MD6xPFA5OiEQvF2= NHWxOW1USU6JRWK=
KYSE-520 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTpTWM2OD1yLkG4NkDPxE1? MVXTRW5ITVJ?
LK-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTNTWM2OD1yLkG4N|A{KM7:TR?= NELtd5BUSU6JRWK=
KNS-81-FD M33Wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LNPGlEPTB;MD6xPFM6PCEQvF2= M4jueHNCVkeHUh?=
IGROV-1 NVzLZXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPjTWM2OD1yLkG4OFQ{KM7:TR?= MkXWV2FPT0WU
DEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LKVmlEPTB;MD6xPFQ2KM7:TR?= MWLTRW5ITVJ?
NCI-H1395 NIezOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMUi2PFIh|ryP Ml3DV2FPT0WU
JEG-3 M{jHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorGTWM2OD1yLkG4O|A2KM7:TR?= NWPwUpZbW0GQR1XS
BCPAP NUPKemdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMUi4O|Ih|ryP MWnTRW5ITVJ?
CAL-27 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMUmwNlIh|ryP MnP3V2FPT0WU
RD M33UdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\tc251UUN3ME2wMlE6OTF|IN88US=> MWnTRW5ITVJ?
RVH-421 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMUmxNVYh|ryP NFW5UIhUSU6JRWK=
Capan-2 NGrpVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHyPWFKSzVyPUCuNVkzPTZizszN NXjGPIY6W0GQR1XS
COLO-680N M3GxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSwO2plUUN3ME2wMlE6OzZ2IN88US=> MXHTRW5ITVJ?
NCI-H1650 NWjQdJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC1bIhEUUN3ME2wMlIxODV5IN88US=> NWm5eItvW0GQR1XS
SBC-5 NUjpe4R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX6bVNKSzVyPUCuNlAyOThizszN MlHYV2FPT0WU
U031 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfiTWM2OD1yLkKwOVQ4KM7:TR?= MYLTRW5ITVJ?
S-117 M1jTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMkC1OlQh|ryP MoDKV2FPT0WU
DoTc2-4510 M1Tae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zw[mlEPTB;MD6yNFc3QSEQvF2= NWHicnRbW0GQR1XS
AM-38 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\MOFRKSzVyPUCuNlA5PDhizszN Mn7QV2FPT0WU
A172 NX;WTIdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHHTWM2OD1yLkKxNFIzKM7:TR?= NHTaeo5USU6JRWK=
HPAF-II MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMkGyOlQh|ryP MmPXV2FPT0WU
769-P NGD0XnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDvRVNKUUN3ME2wMlIyOjhizszN M1ji[XNCVkeHUh?=
MFE-280 NGPadJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPGVnZJUUN3ME2wMlIyOjl6IN88US=> NELTN3JUSU6JRWK=
TE-9 NHjnb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf4XZJKSzVyPUCuNlE4QDZizszN NUjUWIxFW0GQR1XS
C2BBe1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXpTWM2OD1yLkKyNVkh|ryP NYXtd4oyW0GQR1XS
EoL-1-cell MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMkKyNFMh|ryP MYLTRW5ITVJ?
G-361 NWnWVlh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHTVVNKSzVyPUCuNlI3QDJizszN MYLTRW5ITVJ?
KYSE-270 NHLCcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HzcmlEPTB;MD6yN|A5PCEQvF2= MlfyV2FPT0WU
TK10 M3TLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfs[WhKSzVyPUCuNlMyOTdizszN NYXJVW9wW0GQR1XS
ML-2 NILoNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DufWlEPTB;MD6yN|EyQSEQvF2= Ml3LV2FPT0WU
MHH-ES-1 NH;3WpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfEfYFrUUN3ME2wMlI{PjhzIN88US=> MUDTRW5ITVJ?
BHY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjkd3NKSzVyPUCuNlM3QTFizszN MULTRW5ITVJ?
LS-513 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OyTWlEPTB;MD6yN|k3OSEQvF2= NWjFS5RGW0GQR1XS
COLO-678 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDpTWM2OD1yLkK0NFQ1KM7:TR?= MYjTRW5ITVJ?
NCI-H747 MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPqV3l[UUN3ME2wMlI1OTZ7IN88US=> MknYV2FPT0WU
K5 NGXmflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMkSzPEDPxE1? NGCzXINUSU6JRWK=
OS-RC-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPvS4JKSzVyPUCuNlQ2ODlizszN NEHCdVhUSU6JRWK=
KINGS-1 M3PLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq3TWM2OD1yLkK0OVI6KM7:TR?= NGTRRnFUSU6JRWK=
SCC-25 M{nLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLidYI1UUN3ME2wMlI1PTZ|IN88US=> NF:0fJVUSU6JRWK=
CAPAN-1 M37CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrtTWM2OD1yLkK0O|g{KM7:TR?= M4TMUnNCVkeHUh?=
ESS-1 NGXrUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMkS4NFUh|ryP M2\SWXNCVkeHUh?=
TE-6 M3zlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDpOWg{UUN3ME2wMlI2PzVizszN MUPTRW5ITVJ?
LB2518-MEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XyUGlEPTB;MD6yOVc4PyEQvF2= MoPUV2FPT0WU
COLO-800 M4Kxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe1SGxCUUN3ME2wMlI2QDF{IN88US=> MmLIV2FPT0WU
LU-134-A NWTYRW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrJUIxKSzVyPUCuNlYyOzZizszN NGWycY1USU6JRWK=
NCI-H1155 NWDSWY1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Luc2lEPTB;MD6yOlE3OiEQvF2= NWHMUIVRW0GQR1XS
MFM-223 M3q2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMk[zOlMh|ryP MVTTRW5ITVJ?
HTC-C3 NH\te2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXHUVF4UUN3ME2wMlI3PTB4IN88US=> NUHIRmlqW0GQR1XS
HCT-116 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\jVHZKSzVyPUCuNlY2QTlizszN M{jVfnNCVkeHUh?=
Ca-Ski NIHTNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrLelZKSzVyPUCuNlY3PzhizszN MnLqV2FPT0WU
SBC-1 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMk[3OFIh|ryP NEPMO2JUSU6JRWK=
NB69 NYDhToR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[0[pJKSzVyPUCuNlcxQDdizszN Mn7qV2FPT0WU
J82 NVzmXnByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PDW2lEPTB;MD6yO|I3PSEQvF2= NXPERmxWW0GQR1XS
U-118-MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPIfHFKSzVyPUCuNlc2PzlizszN MknaV2FPT0WU
NCI-H1355 NHSzeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMkiwO|Qh|ryP NHHybVJUSU6JRWK=
NCI-H1048 NFzKW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMki5OVYh|ryP M1e3THNCVkeHUh?=
SW954 NWTzdnhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nCSmlEPTB;MD6yPVIzPyEQvF2= NUfoN4FOW0GQR1XS
NMC-G1 NI\HfZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX6UYVRUUN3ME2wMlI6Ojd5IN88US=> M3PuWnNCVkeHUh?=
SW1710 NVL5NZBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\zTWM2OD1yLkK5OFk1KM7:TR?= NWH3T|A{W0GQR1XS
KY821 NG\ibodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfwTWM2OD1yLkK5PFczKM7:TR?= NXfCW5J2W0GQR1XS
HCC38 NFHiUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorMTWM2OD1yLkOwNFc5KM7:TR?= M3ji[HNCVkeHUh?=
NCI-SNU-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T0VmlEPTB;MD6zNFU1KM7:TR?= NFfaT|NUSU6JRWK=
ES8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn1NWk6UUN3ME2wMlMxPzh2IN88US=> Ml7wV2FPT0WU
COLO-792 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwM{GyOVEh|ryP NGq3e5hUSU6JRWK=
BFTC-905 NHW4SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\QS2JKSzVyPUCuN|E2OjFizszN NFXIdGtUSU6JRWK=
ChaGo-K-1 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDiTWM2OD1yLkOxO|E2KM7:TR?= NEHvToNUSU6JRWK=
Daoy NFnyNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjPfYJKSzVyPUCuN|E4OjNizszN MWTTRW5ITVJ?
SJSA-1 MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTpTWM2OD1yLkOxPFQ4KM7:TR?= MUjTRW5ITVJ?
KNS-62 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf5XopKSzVyPUCuN|IxQDhizszN M{\KSHNCVkeHUh?=
CAKI-1 M4Xsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjkTWM2OD1yLkOyNVEyKM7:TR?= NETRZWhUSU6JRWK=
UACC-62 NGGyVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP5TWM2OD1yLkOyNlI4KM7:TR?= MWjTRW5ITVJ?
HuCCT1 NYTmO4I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fnOGlEPTB;MD6zNlI5OyEQvF2= Mnu4V2FPT0WU
CTB-1 NF;lV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwM{K3OVMh|ryP M{\hXnNCVkeHUh?=
NTERA-S-cl-D1 NHzIdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;2TWM2OD1yLkOyPFM3KM7:TR?= MVXTRW5ITVJ?
T-24 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\1ZlY3UUN3ME2wMlM{OTV7IN88US=> NVK2OWhCW0GQR1XS
KYSE-70 M1;uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwM{OyPFMh|ryP NVTvV4IxW0GQR1XS
SW626 NVzLOlJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3sSYlKSzVyPUCuN|M2OzJizszN MXLTRW5ITVJ?
LB996-RCC Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH1TWM2OD1yLkOzOlE6KM7:TR?= M4jR[3NCVkeHUh?=
DMS-273 NVL2V5ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zOOmlEPTB;MD6zN|kyPiEQvF2= NUfR[3dXW0GQR1XS
SW1783 NXnyOGNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnyzTWM2OD1yLkOzPVk4KM7:TR?= MlHSV2FPT0WU
KU812 NULCfVlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG3T|dsUUN3ME2wMlM1ODN6IN88US=> MULTRW5ITVJ?
HSC-2 M3r4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DObWlEPTB;MD6zOFA2OyEQvF2= Mon3V2FPT0WU
A3-KAW NXPlRo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSxTWM2OD1yLkO0NVYzKM7:TR?= Mn7rV2FPT0WU
COLO-684 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwM{S1NFEh|ryP NWPPRYVtW0GQR1XS
NCI-H2405 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTKSZd1UUN3ME2wMlM1PjNzIN88US=> NX;iWHVPW0GQR1XS
NCI-H2228 NXvxZ4p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1qyXmlEPTB;MD6zOVM2PyEQvF2= NVnyb3U3W0GQR1XS
NB13 M4q4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnziTWM2OD1yLkO2PFI6KM7:TR?= MWnTRW5ITVJ?
no-11 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwM{[5OUDPxE1? M4iyNHNCVkeHUh?=
DK-MG NX7KWXZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCzToRDUUN3ME2wMlM4OTh6IN88US=> NEm0T4RUSU6JRWK=
NBsusSR NUX3TZNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG1SJdKSzVyPUCuN|czQDVizszN M2DU[HNCVkeHUh?=
KP-N-YS NXfFNmZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjnN4lxUUN3ME2wMlM4PDZ|IN88US=> MWrTRW5ITVJ?
CFPAC-1 NGi4VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDlTWM2OD1yLkO3OVE5KM7:TR?= MmnxV2FPT0WU
KARPAS-45 NUW5ZoY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\xc2lEPTB;MD6zO|g3OiEQvF2= MWTTRW5ITVJ?
NCI-H1793 M33PNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXKTWM2OD1yLkO4OVEh|ryP MUXTRW5ITVJ?
HCE-T NIHXdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzETWM2OD1yLkO4OlA{KM7:TR?= MYfTRW5ITVJ?
NCI-H520 NHvPeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH6TWM2OD1yLkO4O|A{KM7:TR?= MWTTRW5ITVJ?
HCC2157 M1:yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3GTWM2OD1yLkO4O|gyKM7:TR?= NXrEOFB1W0GQR1XS
EW-18 M4jn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme5TWM2OD1yLkO4PVQyKM7:TR?= NEXjU4hUSU6JRWK=
RO82-W-1 NVzWOolyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwM{m2PVkh|ryP NXLwVYhjW0GQR1XS
HuP-T3 NVLsTVNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfu[VNKSzVyPUCuOFAyPDNizszN MULTRW5ITVJ?
PANC-10-05 NVvZe2VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\tTWM2OD1yLkSxNVch|ryP M{j5enNCVkeHUh?=
NCI-H1703 NWLZeWV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHuTWM2OD1yLkSxOFQ3KM7:TR?= M4jBbHNCVkeHUh?=
TE-10 NXnUWVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LuS2lEPTB;MD60NVQ1PyEQvF2= NE\RSmxUSU6JRWK=
HOS M{TWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fHU2lEPTB;MD60NVY5OiEQvF2= MYDTRW5ITVJ?
LN-405 NHyyVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDyclhKSzVyPUCuOFE3QDdizszN M4DlOXNCVkeHUh?=
A427 M1XFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;WUYtKSzVyPUCuOFE6QDFizszN M3TZR3NCVkeHUh?=
CAL-12T NE\oe49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LiTmlEPTB;MD60Nlc5KM7:TR?= NXy1NlRDW0GQR1XS
SW756 M33EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qxR2lEPTB;MD60OFE5OyEQvF2= M4TCZnNCVkeHUh?=
YAPC NXz0fXFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HFemlEPTB;MD60OVA5KM7:TR?= M2DTc3NCVkeHUh?=
GOTO NF\kOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjNVIJSUUN3ME2wMlQ2OTZizszN NWHlc|hqW0GQR1XS
C3A NH21TYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjlenI1UUN3ME2wMlQ2PDN5IN88US=> MmS5V2FPT0WU
UM-UC-3 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XXWGlEPTB;MD60OVQ4KM7:TR?= M3jqcXNCVkeHUh?=
NCI-H1573 NVPDcIYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNEW1Olkh|ryP M{\NfXNCVkeHUh?=
LS-411N NUPIbm5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjpTWM2OD1yLkS2OVI4KM7:TR?= M3vPSnNCVkeHUh?=
COR-L23 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITP[5VKSzVyPUCuOFY4PjRizszN MVzTRW5ITVJ?
HCE-4 M3rhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17EemlEPTB;MD60O|Q1PiEQvF2= NIPlUY9USU6JRWK=
NCI-H2291 NFK2TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTOXVhKSzVyPUCuOFc5QTZizszN M1LSUnNCVkeHUh?=
A101D M1:3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HZbWlEPTB;MD60PFA2OyEQvF2= M33F[XNCVkeHUh?=
HT-3 M1XyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwNEiyNVch|ryP MkWxV2FPT0WU
HOP-62 NEn6W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXtdI1mUUN3ME2wMlQ6QDZ3IN88US=> M1rWfHNCVkeHUh?=
PC-3 M3;mSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjHVWVSUUN3ME2wMlUyPTB5IN88US=> MX7TRW5ITVJ?
CTV-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwNUK2Olkh|ryP NG\UTWhUSU6JRWK=
PANC-08-13 M1v2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz3TWNwUUN3ME2wMlU{OTd5IN88US=> MmrnV2FPT0WU
CAL-120 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrTTWM2OD1yLkWzN|k6KM7:TR?= NVfHOmdsW0GQR1XS
UMC-11 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPuTWM2OD1yLkW1NlM1KM7:TR?= NYi1O|NFW0GQR1XS
MSTO-211H M3naNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwNUW3OlIh|ryP NGnUfm1USU6JRWK=
NCI-H2126 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf4TWM2OD1yLkW2PFE2KM7:TR?= MmrtV2FPT0WU
SNU-C2B M2PU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\M[WlEPTB;MD61O|k4PyEQvF2= M2XBO3NCVkeHUh?=
DBTRG-05MG MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LETWlEPTB;MD61PFA2OyEQvF2= NH;Nb5VUSU6JRWK=
MKN1 M2DXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3[3NKSzVyPUCuOVg4QDNizszN MkDTV2FPT0WU
ES3 M33Q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXabVBKSzVyPUCuOVkyOjRizszN MUjTRW5ITVJ?
OVCAR-3 NWL5SppUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ObFdKSzVyPUCuOVk{PDFizszN MXXTRW5ITVJ?
ACHN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwNkC1Olkh|ryP NVzQZYo1W0GQR1XS
SW872 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLzTWM2OD1yLk[wO|Y{KM7:TR?= NViyUHV[W0GQR1XS
CP66-MEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXHTWM2OD1yLk[wPVY6KM7:TR?= M{jpdnNCVkeHUh?=
NCI-H661 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjOTWM2OD1yLk[xNVA1KM7:TR?= M3rUR3NCVkeHUh?=
UACC-893 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwNkO2PFEh|ryP MVzTRW5ITVJ?
JVM-3 NXnMcmxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITrXnFKSzVyPUCuOlM5ODRizszN NGLZXlNUSU6JRWK=
SF268 NWLBUlJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInBOJhKSzVyPUCuOlQ{PDlizszN MlHsV2FPT0WU
OCI-AML2 NH\LWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwNkWzPVch|ryP NHrqOoRUSU6JRWK=
RPMI-8226 NUTXV|dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3lNoxoUUN3ME2wMlY3OzJ|IN88US=> M3XKdnNCVkeHUh?=
MKN28 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwNk[2NlQh|ryP MknRV2FPT0WU
MDA-MB-453 NHzSVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nYRmlEPTB;MD62O|E5KM7:TR?= M1jZTHNCVkeHUh?=
BV-173 NXrPVoN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnVZZNRUUN3ME2wMlY5Pjd7IN88US=> NVTu[mdrW0GQR1XS
NCI-H358 NYL5cFZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnBdFlKSzVyPUCuOlg4OjZizszN M4jMbnNCVkeHUh?=
NCI-H1651 NYPlbJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX6dYFKSzVyPUCuO{DPxE1? M3zT[3NCVkeHUh?=
MDA-MB-415 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwN{C4Nlkh|ryP NFjhVo1USU6JRWK=
8305C NWjqVYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPKfoZWUUN3ME2wMlczPDl6IN88US=> NYXzS2I1W0GQR1XS
EFM-19 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrofVJrUUN3ME2wMlc{PjdzIN88US=> Mn\5V2FPT0WU
RERF-LC-MS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;CT4V2UUN3ME2wMlc1PjF|IN88US=> MmfiV2FPT0WU
A388 NEP2fpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj0TWM2OD1yLke2OFY4KM7:TR?= MULTRW5ITVJ?
GI-ME-N M{LJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rEXWlEPTB;MD63O|I{PSEQvF2= MX3TRW5ITVJ?
IGR-1 NXu3bnNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPveJdrUUN3ME2wMlc6ODR|IN88US=> MoPjV2FPT0WU
LNCaP-Clone-FGC MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonUTWM2OD1yLkiwNFA1KM7:TR?= NFjrNmZUSU6JRWK=
SK-MEL-3 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\hcWlEPTB;MD64NVUxQCEQvF2= NVWwOmlTW0GQR1XS
UACC-257 NVvJZ4J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwOEKyN|Eh|ryP M1TocnNCVkeHUh?=
OE33 NWq4bm9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvuTWM2OD1yLki1NVAyKM7:TR?= M2X0XXNCVkeHUh?=
QIMR-WIL MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTFNm1KUUN3ME2wMlg2OTRzIN88US=> MnLqV2FPT0WU
NCI-H2009 NInnV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwOEWzNVEh|ryP NHeyOpdUSU6JRWK=
NCI-H522 M{XTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwOEe3PFMh|ryP M1XZZXNCVkeHUh?=
Saos-2 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHyOY5uUUN3ME2wMlg4QDdzIN88US=> MVPTRW5ITVJ?
NB17 NID4d4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H2c2lEPTB;MD64PFAzPSEQvF2= NHz1b5NUSU6JRWK=
D-392MG NVTLWGFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\NTWM2OD1yLki5N|U3KM7:TR?= M3\wWHNCVkeHUh?=
SHP-77 M4naSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkeyTWM2OD1yLkmwOFg2KM7:TR?= NGTqelJUSU6JRWK=
SK-MEL-30 M{Xucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwOUGxPFUh|ryP MUfTRW5ITVJ?
GCIY M4jKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOUG4OFMh|ryP NWDJbYdoW0GQR1XS
HCC70 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXflNndxUUN3ME2wMlkzODV7IN88US=> MXnTRW5ITVJ?
LU-65 M1T4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofXTWM2OD1yLkmyOVkyKM7:TR?= M2TIWXNCVkeHUh?=
NCI-H1563 NWnlOW83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXq[|FyUUN3ME2wMlk1QDZ3IN88US=> NH[4WFRUSU6JRWK=
KURAMOCHI NWHBdVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLDTWM2OD1yLkm1NVkzKM7:TR?= MljxV2FPT0WU
PA-1 NIDYSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v6fWlEPTB;MD65OVQzPCEQvF2= MYDTRW5ITVJ?
NOS-1 NEntUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPoeZBKSzVyPUCuPVc1QDlizszN M3GwTXNCVkeHUh?=
NCI-H69 M{\NfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\obnRKSzVyPUCuPVc3OzRizszN MX;TRW5ITVJ?
KYSE-450 M4TLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwOUi2NlYh|ryP MmjIV2FPT0WU
8505C NGTs[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzJbFlsUUN3ME2wMlk6QTh{IN88US=> NF3mXlFUSU6JRWK=
TGBC24TKB MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfROlNIUUN3ME2xMlAxODh2IN88US=> NX3tR4ZrW0GQR1XS
PFSK-1 NXXUcZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHwbVRKSzVyPUGuNFE1OjhizszN NEDCZ2ZUSU6JRWK=
EKVX M4WzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInYW|RKSzVyPUGuNFMyOjFizszN MkK1V2FPT0WU
RCM-1 M4jIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zz[GlEPTB;MT6wOVUxPyEQvF2= M4[5V3NCVkeHUh?=
SW900 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrFTWM2OD1zLkC3PFMh|ryP NH;uSIFUSU6JRWK=
D-542MG NVHscIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HkVWlEPTB;MT6wO|g2PSEQvF2= M4rybnNCVkeHUh?=
SK-PN-DW NFzsfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PhcmlEPTB;MT6xNFA2PiEQvF2= M3LFZXNCVkeHUh?=
NCI-H727 NGLidmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:3TWM2OD1zLkGwNVU1KM7:TR?= MkfWV2FPT0WU
SW837 NF7nVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwMUC5OVQh|ryP NXf5RVhNW0GQR1XS
BT-20 NG\zdFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFSySm9KSzVyPUGuNVEzODRizszN NHnMV5FUSU6JRWK=
RH-18 NHviO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvTTWM2OD1zLkGzNVA{KM7:TR?= NH3HUVBUSU6JRWK=
TE-12 M3XIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXq[WxKSzVyPUGuNVM{OzNizszN MlzsV2FPT0WU
NB10 NXz2Nnl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3LTWM2OD1zLkGzN|Q1KM7:TR?= M3TFRnNCVkeHUh?=
AU565 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTETWM2OD1zLkG1PVc{KM7:TR?= MYPTRW5ITVJ?
OAW-42 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHvcmVKSzVyPUGuNVg{ODZizszN NX2yWoxXW0GQR1XS
DJM-1 NXrGOoI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPuTWM2OD1zLkG5PFgyKM7:TR?= M4\neHNCVkeHUh?=
HH NH;vdYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\QTWM2OD1zLkKzPFMyKM7:TR?= MYHTRW5ITVJ?
LAMA-84 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nv[2lEPTB;MT6yO|M6PCEQvF2= M{jrd3NCVkeHUh?=
KNS-42 NF74OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTOTWM2OD1zLkOwNlk3KM7:TR?= NYnrTZQ{W0GQR1XS
NCI-H2052 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LPU2lEPTB;MT6zNFUxPyEQvF2= MWLTRW5ITVJ?
MLMA MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwM{K0NFch|ryP MnnLV2FPT0WU
NB12 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq3TZpKSzVyPUGuN|U3OzZizszN MkDrV2FPT0WU
NCI-H1838 NEfzXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwM{[zNFYh|ryP MnvxV2FPT0WU
NCI-H526 M1XsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfXWlZCUUN3ME2xMlM4QDV|IN88US=> MnT1V2FPT0WU
LS-123 NGrNNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTZTWM2OD1zLkO5NFk1KM7:TR?= NXX2R3dTW0GQR1XS
HDLM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7zeHI1UUN3ME2xMlM6OjdzIN88US=> NXP5SmcxW0GQR1XS
MC-IXC M2raVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTpTWM2OD1zLkSyN|cyKM7:TR?= M4XRVXNCVkeHUh?=
HCT-15 NUPJ[3RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WzSmlEPTB;MT60N|A3QCEQvF2= NEnJSIlUSU6JRWK=
NCI-H596 NVfPTWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\oVmlEPTB;MT60OVA3OSEQvF2= M4jKVnNCVkeHUh?=
ZR-75-30 NHXBdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\KeWZKSzVyPUGuOFcxQDJizszN NYL3VWRwW0GQR1XS
A704 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\3SZRKSzVyPUGuOlY2PjNizszN MVXTRW5ITVJ?
OVCAR-4 M2i4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHHZYFOUUN3ME2xMlY6PjB5IN88US=> NULmS2NmW0GQR1XS
SW1417 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwN{K4OFkh|ryP NWrVcJB1W0GQR1XS
CAS-1 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLyeXZKSzVyPUGuO|M6OzZizszN MUDTRW5ITVJ?
IST-SL1 NX\XTFhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fLTWlEPTB;MT63PVc2QSEQvF2= NG\uT2VUSU6JRWK=
A253 M1TUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFwOEKyN|kh|ryP NH\PPHlUSU6JRWK=
EW-16 NUPUSII4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofsTWM2OD1zLkiyPFc2KM7:TR?= MnrIV2FPT0WU
SK-NEP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nVc2lEPTB;MT64Olk5QCEQvF2= M3GwUHNCVkeHUh?=
NCI-H226 NWX1WIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrI[VJQUUN3ME2xMlg6OzV7IN88US=> NF7ySVBUSU6JRWK=
HOP-92 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrjTWM2OD1zLkm2NFk6KM7:TR?= M2jr[3NCVkeHUh?=
NCI-H441 NYHWcXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrPTWM2OD1{LkCyN|M4KM7:TR?= Ml3lV2FPT0WU
LU-139 NEHMeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy3UZk6UUN3ME2yMlA{OTF2IN88US=> Ml\TV2FPT0WU
SJRH30 NVPCdVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\UTWM2OD1{LkC0NlU{KM7:TR?= MV;TRW5ITVJ?
MG-63 NF;SNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwMUSxNVEh|ryP MkHJV2FPT0WU
NH-12 MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPoTWM2OD1{LkG1NFA3KM7:TR?= NW\mXVE5W0GQR1XS
NB7 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjIWFZ[UUN3ME2yMlE6Pjd|IN88US=> NED6[HVUSU6JRWK=
LB771-HNC NULMVWpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\oTWM2OD1{LkKwOVk2KM7:TR?= NFzKenhUSU6JRWK=
HCC1569 NXW5Z5NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HtNWlEPTB;Mj6yOFU5OyEQvF2= NGrRUmtUSU6JRWK=
D-283MED M1WxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDPW45lUUN3ME2yMlI1Pzh{IN88US=> M3SxbHNCVkeHUh?=
J-RT3-T3-5 NYCyUY0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJwMkWzOVEh|ryP M{fXcXNCVkeHUh?=
ATN-1 NHywU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjPZXVsUUN3ME2yMlM{ODh{IN88US=> Ml\HV2FPT0WU
HCC1954 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfwbHdKSzVyPUKuN|Q1ODhizszN NWTFbYRZW0GQR1XS
SCC-15 M4HsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LCSWlEPTB;Mj6zPVMyOiEQvF2= NVTWXXZtW0GQR1XS
COLO-668 MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJwNEOyJO69VQ>? NH3uO2ZUSU6JRWK=
LB373-MEL-D M2XmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJwNUS2O|ch|ryP NGHqV4dUSU6JRWK=
no-10 NG\UfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK1V3dKSzVyPUKuOVQ6PDdizszN MoTFV2FPT0WU
HT-1197 MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;QSGlKSzVyPUKuOlMyQDhizszN MYPTRW5ITVJ?
DU-145 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H3[GlEPTB;Mj63PVE3OiEQvF2= MVHTRW5ITVJ?
SK-N-AS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrBZZBKSzVyPUKuPFQ3QTJizszN MkSyV2FPT0WU
MOLT-4 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwOEWzNlIh|ryP MWfTRW5ITVJ?
EW-22 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S0cmlEPTB;Mj65Nlg1OSEQvF2= M{nl[3NCVkeHUh?=
DB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJwOUe3OVkh|ryP NUTZR2M2W0GQR1XS
HL-60 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNwMESzO|Yh|ryP NWj2cVlYW0GQR1XS
SK-N-DZ MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO0fI9KSzVyPUOuNFUxPzVizszN MmHtV2FPT0WU
NY MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqwTWM2OD1|LkC4OVQzKM7:TR?= NGHFNXVUSU6JRWK=
T47D M3zvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnoTWM2OD1|LkGwOVU5KM7:TR?= NELjUYFUSU6JRWK=
NCI-H2029 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjKW49KSzVyPUOuNlI1PzdizszN NWW1e4YyW0GQR1XS
KARPAS-299 NHLkPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn1TWM2OD1|LkK2NFI4KM7:TR?= MYnTRW5ITVJ?
KM-H2 NHfPNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rJNWlEPTB;Mz6zNFY5KM7:TR?= MmHEV2FPT0WU
CHP-134 NXXYZlBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3OPI5uUUN3ME2zMlQ4OzlizszN M{XRWnNCVkeHUh?=
22RV1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3hbHVKSzVyPUOuOFkyPjhizszN NIXhXJNUSU6JRWK=
NB5 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLhTWM2OD1|LkWwOlg6KM7:TR?= NVnxS2Q{W0GQR1XS
CW-2 NFnBOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTnTWM2OD1|LkW1N|E1KM7:TR?= M3vkXnNCVkeHUh?=
EFO-21 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nlNGlEPTB;Mz61Olk1KM7:TR?= M2PBUnNCVkeHUh?=
HuH-7 NGL5SFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TFVWlEPTB;Mz61PFQyPCEQvF2= M2DwdHNCVkeHUh?=
ALL-PO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLrdVNKSzVyPUOuOlI{OzVizszN MojOV2FPT0WU
EM-2 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNwNkmwNVEh|ryP MlfWV2FPT0WU
KLE M{TWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT3TWM2OD1|LkezNFI6KM7:TR?= NITxXmhUSU6JRWK=
NEC8 NHTmO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P4WGlEPTB;Mz65NVgxQCEQvF2= MnmxV2FPT0WU
KP-N-YN MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW3fJl7UUN3ME2zMlk{PDd4IN88US=> MUDTRW5ITVJ?
SK-MEL-1 NEHZTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXNfZhKSzVyPUSuNFM2OThizszN Mn33V2FPT0WU
CAL-54 M{jrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnnTWM2OD12LkC1PVEh|ryP NEn3SpdUSU6JRWK=
MS-1 NImyWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DnNWlEPTB;ND6xOlE2PSEQvF2= MkO5V2FPT0WU
NCI-H209 NWDPd|ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTTSYREUUN3ME20MlI6QTl7IN88US=> MmHkV2FPT0WU
NOMO-1 NEn1SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGzTWM2OD12LkOyNVMyKM7:TR?= NXq3fGhrW0GQR1XS
RPMI-2650 M4\F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;hUGlEPTB;ND6zOlMzPyEQvF2= M4PpWHNCVkeHUh?=
NCI-H810 NWH0W|Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f5cWlEPTB;ND6zPVc{PiEQvF2= NHTVe5NUSU6JRWK=
Ca9-22 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTRwNEW2PVEh|ryP Mn\sV2FPT0WU
ES4 NIP2eJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTRwNEewPVUh|ryP NUOwbZdkW0GQR1XS
ES6 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7mVWc6UUN3ME20MlQ6PjV5IN88US=> NIPSVJhUSU6JRWK=
DMS-114 NV\rZXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjVWphmUUN3ME20MlU1PjlzIN88US=> MoPaV2FPT0WU
ONS-76 NWnqTZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:0XWlEPTB;ND61O|k2KM7:TR?= NFW0WWNUSU6JRWK=
K-562 MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq3PY9CUUN3ME20Mlc{QDF2IN88US=> MWjTRW5ITVJ?
MHH-NB-11 NVWxXVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRwN{W0OlEh|ryP NVjF[FZiW0GQR1XS
Calu-3 M{fQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGxcnN7UUN3ME20Mlc5PTR6IN88US=> NY\zco5TW0GQR1XS
HT55 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPaTWM2OD12Lki0OVQ2KM7:TR?= NUPCSIw2W0GQR1XS
SK-N-FI NHnHcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LwZWlEPTB;ND64OVAxQSEQvF2= NVvNS|dCW0GQR1XS
ES1 NIPqNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHoTWM2OD12Lki2NFU4KM7:TR?= NY[w[WtlW0GQR1XS
SF126 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTveVlnUUN3ME20Mlk{OTh2IN88US=> M37IVnNCVkeHUh?=
ES5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTrTWM2OD13LkGyOFI4KM7:TR?= MVzTRW5ITVJ?
LoVo NV73d2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\MXFZKSzVyPUWuNVU5PzFizszN NYCyZnA6W0GQR1XS
SNU-387 NUnWb2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;DTWM2OD13LkOyN|M6KM7:TR?= Mk\GV2FPT0WU
C8166 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVwM{[zN|kh|ryP M3zvXHNCVkeHUh?=
LS-1034 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPmUnJjUUN3ME21MlQzOzB5IN88US=> NGDRVodUSU6JRWK=
GR-ST NIrH[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrJN41KSzVyPUWuOVIzODFizszN MlrVV2FPT0WU
NCI-H1092 M3ewbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK5TWM2OD13LkeyPFQ{KM7:TR?= NYrIOIFIW0GQR1XS
647-V M{X0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT2TWM2OD13Lke0O|A3KM7:TR?= NWLtTnlLW0GQR1XS
EW-13 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwN{[2Nlch|ryP NGTNdoZUSU6JRWK=
KGN NHnBfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Tqb2lEPTB;Nj6wPVkzOSEQvF2= NVvLWoVpW0GQR1XS
D-423MG MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vlWWlEPTB;Nj60NFI5PCEQvF2= M4PHNXNCVkeHUh?=
ECC10 NEDzeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDpNYpKSzVyPUeuNVAyODFizszN NYP0bmU6W0GQR1XS
TE-5 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tsc2lEPTB;Nz60NVI6QCEQvF2= M{L4dnNCVkeHUh?=
P12-ICHIKAWA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTdwNEW1NlMh|ryP NWrTTI1CW0GQR1XS
NCI-H82 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL6PIZKSzVyPUeuOFU4ODFizszN NYLP[5RnW0GQR1XS
NCI-H1993 M4LIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PQTmlEPTB;Nz64N|A3OyEQvF2= M1zlT3NCVkeHUh?=
RH-1 NXXm[IhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTdwOEWyOFQh|ryP M2XxbHNCVkeHUh?=
SW948 M1nJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm3c2xKSzVyPUeuPVYxPDlizszN MVTTRW5ITVJ?
CAL-33 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13MTGlEPTB;Nz65PVk{QCEQvF2= MmG3V2FPT0WU
U-266 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzPTWM2OD16LkG1O|c4KM7:TR?= M1\6WHNCVkeHUh?=
CAL-72 M1;lXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TuO2lEPTB;OD6yNFMzKM7:TR?= NXLRenVmW0GQR1XS
SNU-423 M4D3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTlwM{[2OlYh|ryP NXrzZ|VVW0GQR1XS
KG-1 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrRS2ExUUN3ME25MlU5PDV4IN88US=> NEnCbW1USU6JRWK=
HCC1395 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[5THFTUUN3ME25MlkzOzV{IN88US=> NYWyeFYxW0GQR1XS
BE-13 M{fxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLSTWM2OD1zMD64PFkzKM7:TR?= Mn\yV2FPT0WU
MKN7 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW2TWM2OD1zMD65O|Y2KM7:TR?= MXjTRW5ITVJ?
697 M2PnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTYeIV3UUN3ME2xNU4yPDd{IN88US=> NVzO[|ZHW0GQR1XS
LU-135 NXi2[npPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfWTWM2OD1zMT6yN|A4KM7:TR?= MYHTRW5ITVJ?
ES7 MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDzPGZKSzVyPUGxMlM{OTNizszN NGPMRYtUSU6JRWK=
SK-HEP-1 NG\KeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17yWGlEPTB;MUGuO|Y1PiEQvF2= M2ntRnNCVkeHUh?=
BEN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXFfFBKSzVyPUGxMlg2OSEQvF2= NHi3WYVUSU6JRWK=
NCI-H1770 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[yTWM2OD1zMj6xNlYh|ryP NWPVWHBmW0GQR1XS
SW13 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PoPGlEPTB;MUKuNVU1OSEQvF2= MnzzV2FPT0WU
MZ1-PC M1Lnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\3XmlEPTB;MUKuOVQ2OiEQvF2= MYDTRW5ITVJ?
Mo-T NVjrUIQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfGR|JXUUN3ME2xNk44PDJzIN88US=> MYDTRW5ITVJ?
HLE MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf0[VNHUUN3ME2xNk45OjF3IN88US=> MXXTRW5ITVJ?
RCC10RGB NVe1[XRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF|Lk[3NUDPxE1? MmTGV2FPT0WU
COLO-320-HSR NUHDb4FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTVTWM2OD1zMz63N|gyKM7:TR?= NETvN4JUSU6JRWK=
BHT-101 NXHYXms{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonPTWM2OD1zMz64N|Q2KM7:TR?= M3XpdXNCVkeHUh?=
OCUB-M NG\JOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXTTWM2OD1zND6xOlAzKM7:TR?= NV\TNoJUW0GQR1XS
MEG-01 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e3dmlEPTB;MUSuN|cxQCEQvF2= MmGyV2FPT0WU
RS4-11 M2TLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jHWmlEPTB;MUSuO|QzKM7:TR?= NETuOG5USU6JRWK=
MN-60 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nZNGlEPTB;MUSuO|g6PCEQvF2= MnTQV2FPT0WU
NCI-H1304 NFzBfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLTTJJCUUN3ME2xOU4xPDJ3IN88US=> NIrsRYRUSU6JRWK=
Ramos-2G6-4C10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme5TWM2OD1zNT6wOVgyKM7:TR?= MYfTRW5ITVJ?
NCI-H2342 NYTjO45qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DEXWlEPTB;MUWuNlA1PCEQvF2= MmPTV2FPT0WU
LAN-6 NG\ydWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF3LkS0NVQh|ryP M4jocHNCVkeHUh?=
JVM-2 NFq0c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPxTWM2OD1zNT61O|Q5KM7:TR?= MWHTRW5ITVJ?
P30-OHK NVm1bWlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvRXlFWUUN3ME2xOk4xPjF2IN88US=> M3H0[XNCVkeHUh?=
C-33-A NGnhNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvOTWM2OD1zNj62NlE1KM7:TR?= M1TqNHNCVkeHUh?=
RPMI-8866 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fO[2lEPTB;MU[uPFQ6PiEQvF2= NEHRTpZUSU6JRWK=
NCI-H630 NE\YOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\3Z2lEPTB;MU[uPFU{PyEQvF2= MmDkV2FPT0WU
KYSE-140 NWj0OVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorRTWM2OD1zNz6yNFI5KM7:TR?= MoXHV2FPT0WU
T84 MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S5emlEPTB;MUiuPFY6PSEQvF2= MnLJV2FPT0WU
KU-19-19 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF6Lkm2NFgh|ryP M3nqWnNCVkeHUh?=
BALL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HDOWlEPTB;MUmuN|M6QSEQvF2= Mo\4V2FPT0WU
Calu-6 NIfyVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF7LkS5NkDPxE1? MUHTRW5ITVJ?
EGI-1 NUTxSZByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M173VGlEPTB;MUmuOVk5KM7:TR?= MV3TRW5ITVJ?
MFH-ino NVrVUINTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXwT5pKSzVyPUG5Mlc1PTRizszN NY\MRZdYW0GQR1XS
GB-1 NFWzVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnuSpNKSzVyPUKwMlM2OzVizszN MXrTRW5ITVJ?
NCI-H1693 MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\ITWM2OD1{MD62OVA2KM7:TR?= MWjTRW5ITVJ?
SW1116 NXK0XI5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJyLkmzOlIh|ryP NVW0Z3lkW0GQR1XS
H-EMC-SS MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHGZot1UUN3ME2yNk4xPDVizszN MXzTRW5ITVJ?
D-502MG M37JcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrHeVBDUUN3ME2yNk45OjZzIN88US=> M2HWdHNCVkeHUh?=
IA-LM NHXGUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ|LkK0PVMh|ryP MVjTRW5ITVJ?
SW1463 M4X5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJ|Lke5JO69VQ>? NFzLTXpUSU6JRWK=
JAR MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DVWmlEPTB;MkSuN|I6OyEQvF2= MoW5V2FPT0WU
HT MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\LO|FKSzVyPUK0MlQ4PTNizszN M13IVXNCVkeHUh?=
LCLC-103H MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK2SG5KSzVyPUK0Mlg1PDlizszN M3i5OnNCVkeHUh?=
SNU-449 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLpTWM2OD1{ND64O|QyKM7:TR?= MnfEV2FPT0WU
KE-37 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvTNpFJUUN3ME2yOU4xQTJ6IN88US=> NE\sd4NUSU6JRWK=
NCI-H1623 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ5LkGzNFMh|ryP MWHTRW5ITVJ?
MOLT-13 NXPxVndnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ5LkO1NVYh|ryP MnPVV2FPT0WU
COLO-741 NEjoW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTNzLkOzN|Mh|ryP NGi2XJpUSU6JRWK=
NB6 NHKyPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\kUld2UUN3ME2zNk4zQDd4IN88US=> MmLNV2FPT0WU
MOLT-16 NFPxTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vXe2lEPTB;M{OuNFA2PSEQvF2= MULTRW5ITVJ?
IST-MES1 NWnFVlRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqwTWM2OD1|ND6wOVQyKM7:TR?= M4rE[HNCVkeHUh?=
A4-Fuk NWPJR3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTXSmdKSzVyPUO1MlA3PiEQvF2= NX:yVm9VW0GQR1XS
CAL-85-1 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r5UWlEPTB;M{WuNlgyPyEQvF2= M4T5XnNCVkeHUh?=
CCRF-CEM MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKwXGE6UUN3ME2zO{4yPTN4IN88US=> NFrSeJVUSU6JRWK=
HAL-01 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;EcGlEPTB;M{iuOFg5QSEQvF2= MXPTRW5ITVJ?
HEL M{Dwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3C[GJEUUN3ME20N{4{PDB7IN88US=> Mo\HV2FPT0WU
EW-1 NWnzd|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP4[lBKSzVyPUSzMlQ4PjhizszN MXrTRW5ITVJ?
MDA-MB-231 NXfXVIVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y5[GlEPTB;NEWuNVE6QSEQvF2= MkjCV2FPT0WU
ABC-1 M1jJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLLb5lKSzVyPUS2Mlg2OzhizszN MnzHV2FPT0WU
NCI-H446 NHXnPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTR6LkWwOVgh|ryP NGDRWmlUSU6JRWK=
MHH-PREB-1 M3PzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR7Lk[wNFch|ryP NVv1ZWVyW0GQR1XS
DOHH-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLGc|dxUUN3ME20PU43PjV4IN88US=> M2H5OHNCVkeHUh?=
GCT Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13BN2lEPTB;NEmuOlk4PiEQvF2= NG\UdVRUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID